Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

← catalyst calendar

NCT05609630 · readout ≤ 1,045 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

90estimated

Sites

Countries

Argentina, Australia, Austria +14

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-10-02

actual

When the study began enrolling

Primary completion

Jun 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2029

estimated

The whole study's end, after follow-up

First posted

2022-11-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Juvenile Idiopathic Arthritis

Interventions

Drug: Upadacitinib — also filed as RINVOQ, ABT-494
Drug: Tocilizumab

Primary outcomes

what the primary-completion date above is the date OF

Percentage of Participants Achieving Adapted systemic Juvenile Idiopathic Arthritis (sJIA) American College of Rheumatology (ACR) 30 Response

measured At Week 12

Number of Participants with Adverse Events (AEs)

measured Up to Approximately Week 52

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed